1-6 of 6
Emiliano Cocco
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C165: Zurletrectinib, a next-generation TRK inhibitor shows strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation drugs

Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina, Supipi Auwardt, Michelle de Marchena, Shaza Ahmed, Nicole Bremer, Soo-Ryum Yang, Alexander Drilon, Emiliano Cocco
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C165.
https://doi.org/10.1158/1535-7163.TARG-23-C165
Published: 01 December 2023
View article titled, Abstract C165: Zurletrectinib, a next-generation TRK inhibitor shows strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation drugs
Journal Articles

Abstract B169: Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2

Emiliano Cocco, F. Javier Carmona, Helen H. Won, Michael F. Berger, David M. Hyman, Valentina Rossi, Carmen Chan, Alyssa Moriarty, Kyriakos P. Papadopoulos, Michael J. Wick, James Cownie, Ivana Sarotto, Richard E. Cutler, Francesca Avogadri-Connors, Peter Savas, Alshad S. Lalani, Valentina Boni, Sherene Loi, Jose Baselga, Filippo Montemurro, Maurizio Scaltriti
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B169.
https://doi.org/10.1158/1535-7163.TARG-17-B169
Published: 01 January 2018
View article titled, Abstract B169: Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
Journal Articles

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

Emiliano Cocco, Yang Deng, Erik M. Shapiro, Ileana Bortolomai, Salvatore Lopez, Ken Lin, Stefania Bellone, Jiajia Cui, Gulden Menderes, Jonathan D. Black, Carlton L. Schwab, Elena Bonazzoli, Fan Yang, Federica Predolini, Luca Zammataro, Gary Altwerger, Christopher de Haydu, Mitchell Clark, Julio Alvarenga, Elena Ratner, Masoud Azodi, Dan-Arin Silasi, Peter E. Schwartz, Babak Litkouhi, W. Mark Saltzman, Alessandro D. Santin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (2): 323–333.
https://doi.org/10.1158/1535-7163.MCT-16-0501
Published: 02 February 2017
View article titled, Dual-Targeting Nanoparticles for <em>In Vivo</em> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells
Open the PDF for Dual-Targeting Nanoparticles for <em>In Vivo</em> Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells in another window
Includes: Supplementary data
Journal Articles

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

Jonathan Black, Gulden Menderes, Stefania Bellone, Carlton L. Schwab, Elena Bonazzoli, Francesca Ferrari, Federica Predolini, Christopher De Haydu, Emiliano Cocco, Natalia Buza, Pei Hui, Serena Wong, Salvatore Lopez, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Babak Litkouhi, Peter E. Schwartz, Peter Goedings, Patrick H. Beusker, Miranda M.C. van der Lee, C. Marco Timmers, Wim H.A. Dokter, Alessandro D. Santin
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (8): 1900–1909.
https://doi.org/10.1158/1535-7163.MCT-16-0163
Published: 03 August 2016
View article titled, SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Open the PDF for SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression in another window
Includes: Supplementary data
Journal Articles

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

Salvatore Lopez, Emiliano Cocco, Jonathan Black, Stefania Bellone, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Carlton L. Schwab, Diana P. English, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Corrado Terranova, Roberto Angioli, Alessandro D. Santin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2519–2526.
https://doi.org/10.1158/1535-7163.MCT-15-0383
Published: 03 November 2015
View article titled, Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)

Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, Francesca Casagrande, Marta Bellone, Maysa Abu-Khalaf, Natalia Buza, Fattaneh A. Tavassoli, Pei Hui, Dominik Rüttinger, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, Thomas J. Rutherford, Sergio Pecorelli, Alessandro D. Santin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 57–66.
https://doi.org/10.1158/1535-7163.MCT-09-0675
Published: 12 January 2010
View article titled, Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)
Open the PDF for Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201) in another window